NanoManganese (NP02) / Medesis - LARVOL DELTA

NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19) (clinicaltrials.gov) - P1/2 | N=7 | Terminated | Sponsor: Medesis Pharma SA | N=120 ➔ 7 | Recruiting ➔ Terminated; the number of patients recruited was not reached because covid cases were low

Enrollment change • Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19) (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: Medesis Pharma SA

New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases